CA
NZ
UK
AU
IND
US
Anavex Life Sciences (NASDAQ:AVXL) shares were trading near their 52-week low at USD 1.23 on October 19, 2026, down 6.49%. Since midyear, the clinical-stage biotechnology company has filed amended reports on internal controls, regained compliance with a Nasdaq filing rule, held a contested annual …
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) shares were trading near their 52-week low at USD 2.83 on October 19, 2026, up 0.35%. The clinical-stage company develops oral small-molecule therapies for RAS-pathway cancers. It released new data for its BBO-8520 KRAS G12C program on September 8 and …
BlossomHill Therapeutics (NASDAQ:BLSM) shares were trading near their 52-week low at USD 14.07 on October 19, 2026, up 0.93%. The clinical-stage cancer drug developer listed in August, filed its first quarterly report as a public company on September 18 and drew an initiation from …
Benitec (NASDAQ:BNTC) shares were trading near their 52-week low at USD 8.39 on October 19, 2026, up 3.45%. The gene therapy developer's latest update came on October 5, when it said the FDA was still discussing a pivotal design for its BB-301 candidate and …
Cabaletta Bio (NASDAQ:CABA) shares were trading near their 52-week low at USD 1.49 on October 19, 2026, up 5.67%. The clinical-stage biotechnology company develops the CAR T therapy rese-cel for autoimmune disease. Its latest quarterly report carries a going concern conclusion, while warrant exercises …
Coherus Oncology (NASDAQ:CHRS) shares were trading near their 52-week low at USD 0.9771 on October 19, 2026, down 1.30%. Since its August 5 second quarter report, the commercial-stage company behind the nasopharyngeal carcinoma therapy LOQTORZI has declared a contingent value rights dividend for its …
Conexeu Sciences (NASDAQ:CNXU) shares were trading near their 52-week low at USD 3.20 on October 19, 2026, up 4.41%. The regenerative medicine company listed on Nasdaq on May 21, 2026, has no commercial sales and carries going concern language in its latest quarterly report. …
UBS raised its target to $35 from $32 on August 7 and carries a Neutral rating. BMO Capital Markets raised its target to $43 from $40 on October 9 and carries an Outperform rating. The price sits above UBS's target and below BMO's. These …
Morgan Stanley raised its price target on Arcutis to $38 from $34 on August 6, 2026, the day after the second-quarter report, and kept an Overweight rating. The share price of USD 32.50 sits below that target. That is the firm's own view, not …
Brokerage actions since the July 29 results include a Jefferies upgrade to Hold from Underperform that day, with a $13 target. Wells Fargo raised its target to $16 from $14 on July 30, keeping Overweight. UBS started coverage at Neutral with a $16 target …
Please wait processing your request...